Is it fair to equate Trump with Nixon?

On the 43rd anniversary of Richard Nixon's resignation, historian Timothy Naftali warns we shouldn't be so quick to liken President Trump to him.

From his earliest days in the White House, President Donald Trump has inspired some to muse on his perceived similarities to Richard Nixon. But it wasn’t until after President Trump fired FBI director James Comey on May 9—in the midst of an investigation into whether members of the Trump campaign colluded with the Russian government to influence the outcome of the 2016 election—that the debate came to dominate the headlines: Were we witnessing the Watergate of a new generation?

Timothy Naftali, clinical associate professor of history and public service and co-director of New York University’s Center for the United States and the Cold War, served as the founding director of the Richard Nixon Presidential Library and Museum in Yorba Linda, California, where he was tasked with telling the story of Watergate from a nonpartisan perspective and overseeing the public release of 1.3 million presidential documents and 700 hours of audio recordings.

On the 43th anniversary of the day Nixon resigned, Naftali reflects on Nixon’s legacy in the context of a new presidential controversy.

The post Is it fair to equate Trump with Nixon? appeared first on Futurity.

Plus de Futurity

Futurity2 min de lectureWellness
‘Virtual Biopsy’ Device Detects Skin Tumors In 15 Minutes
A new “virtual biopsy” device uses sound vibrations and pulses of near-infrared light instead of a scalpel to quickly determine a skin lesion’s depth and potential malignancy, a new study reports. The ability to analyze a skin tumor non-invasively co
Futurity2 min de lectureScience
Morning Exercise Or Evening? Both Have Perks
The benefits of exercise may differ depending on the time of day when you work out, a new study in mice suggests. Too little sleep can have severe health consequences, but researchers are still making discoveries confirming that the body’s circadian
Futurity2 min de lectureScience
Clues To Side Effect May Prolong Prostate Cancer Survival
Scientists believe they’ve figured out why a common drug for late-stage prostate cancer often loses effectiveness and can even make things worse. The drug, enzalutamide, stops working after four or five months and appears to have a dual function that